Evidence has accumulated suggesting that women who take estrogens after the menopause have decreased rates of arteriosclerosis. The proposed research will investigate the effects of estrogen with and without progestin on several major influences on arteriosclerosis: concentration and metabolism of the plasma lipoproteins, blood pressure and vascular responsiveness to pressors and the activity of the hemostatic system. The overall goals are, 1) to determine the dose of estrogens that could favorably alter risk factors for vascular disease and 2) to understand the mechanisms of action of estrogen. Two prospective studies are proposed. Each will involve administering sex hormones for 3 month periods to healthy postmenopausal women in a placebo controlled double-blind crossover design. Each subject will thus serve as her own control. 1. Estrogen alone. Thirty subjects will receive conjugated equine estrogens (Premarin) 0.3mg, 0.6mg, and 1.25mg daily. 2. Estrogen with progesterone. Using the results of the previous trial, 30 women will receive an estrogen alone and with cyclical administration of progesterone. In these protocols, the following variables will be measured: a) detailed lipid and apoprotein analysis of the lipoproteins VLDL, LDL, HDL2 and HDL3; b) Lipid metabolism: Hepatic and extrahepatic lipoprotein lipases which control HDL metabolism; LDL receptors and cholesterol synthesis in the subjects' blood mononuclear cells, and VLDL subfractions and the direct uptake of the subjects' VLDL by cultured macrophages; c) blood pressure on multiple occasions at home and in clinic; d) vascular resistance and reactivity to angiotensin and norepinephrine; and e) indices of hypercoagulability such as prothrombin activation fragment, protein C, thrombin-antithrombin complex, and fibrinopeptide A. Knowledge gained from these studies may provide information for rational prescribing of estrogens to postmenopausal women.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL034980-02
Application #
3348414
Study Section
Reproductive Endocrinology Study Section (REN)
Project Start
1986-09-01
Project End
1989-08-31
Budget Start
1987-09-01
Budget End
1988-08-31
Support Year
2
Fiscal Year
1987
Total Cost
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02115
Desai, Nirav K; Ooi, Esther M; Mitchell, Paul D et al. (2015) Metabolism of apolipoprotein A-II containing triglyceride rich ApoB lipoproteins in humans. Atherosclerosis 241:326-33
Zheng, Chunyu; Khoo, Christina; Furtado, Jeremy et al. (2010) Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype. Circulation 121:1722-34
Mendivil, Carlos O; Zheng, Chunyu; Furtado, Jeremy et al. (2010) Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins. Arterioscler Thromb Vasc Biol 30:239-45
Zheng, Chunyu; Khoo, Christina; Furtado, Jeremy et al. (2008) Dietary monounsaturated fat activates metabolic pathways for triglyceride-rich lipoproteins that involve apolipoproteins E and C-III. Am J Clin Nutr 88:272-81
Zheng, Chunyu; Khoo, Christina; Ikewaki, Katsunori et al. (2007) Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions. J Lipid Res 48:1190-203
Campos, H; Perlov, D; Khoo, C et al. (2001) Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia. J Lipid Res 42:1239-49
Tomiyasu, K; Walsh, B W; Ikewaki, K et al. (2001) Differential metabolism of human VLDL according to content of ApoE and ApoC-III. Arterioscler Thromb Vasc Biol 21:1494-500
Khoo, C; Campos, H; Judge, H et al. (1999) Effects of estrogenic oral contraceptives on the lipoprotein B particle system defined by apolipoproteins E and C-III content. J Lipid Res 40:202-12
Walsh, B W; Spiegelman, D; Morrissey, M et al. (1999) Relationship between serum estradiol levels and the increases in high-density lipoprotein levels in postmenopausal women treated with oral estradiol. J Clin Endocrinol Metab 84:985-9
Su, W; Campos, H; Judge, H et al. (1998) Metabolism of Apo(a) and ApoB100 of lipoprotein(a) in women: effect of postmenopausal estrogen replacement. J Clin Endocrinol Metab 83:3267-76

Showing the most recent 10 out of 18 publications